زائر
والدي يعاني من سرطان كولون مرحلة رابعة و قيم بعمل هذا الفحص ، هل يمكنكم القول لنا اذا هذا العلاج يكون فعال في هذه الحالة ام لا
Specimen Type:
Block [Pathology # : S22-549-1A]
Mutations:
Codon 12; 13; 59; 61; 117; 146
Technique:
Biocartis ,Idylla
Result:
NRAS Codon 12
Not Detected
NRAS Codon 13
Not Detected
NRAS Codon 59
Not Detected
NRAS Codon 61
Not Detected
NRAS Codon 117
Not Detected
NRAS Codon 146
Not Detected
Interpretation:
The submitted specimen does not show any mutations in codons 12, 13, 59, 61, 117 and 146 of the NRAS gene.
Comment:
The test has been performed on the above-submitted pathology specimen. Please always refer to the block number for adequate interpretation and clinical correlation. A negative result does not exclude the presence of other mutations in the NRAS gene currently not detected through this methodology. However, the above mutations are the most clinically relevant described so far in the literature.
Disclaimer:
This testing was adopted and its performance characteristics were determined by the Molecular Diagnostics Laboratory at the American University of Beirut Medical Center. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes.
Interpretation is done by Rami Mahfouz, MD on 26/01/22 at 09:24 PM.
Specimen Type:
Block [Pathology # : S22-549-1A]
Mutations:
Codon 12; 13; 59; 61; 117; 146
Technique:
Biocartis ,Idylla
Result:
NRAS Codon 12
Not Detected
NRAS Codon 13
Not Detected
NRAS Codon 59
Not Detected
NRAS Codon 61
Not Detected
NRAS Codon 117
Not Detected
NRAS Codon 146
Not Detected
Interpretation:
The submitted specimen does not show any mutations in codons 12, 13, 59, 61, 117 and 146 of the NRAS gene.
Comment:
The test has been performed on the above-submitted pathology specimen. Please always refer to the block number for adequate interpretation and clinical correlation. A negative result does not exclude the presence of other mutations in the NRAS gene currently not detected through this methodology. However, the above mutations are the most clinically relevant described so far in the literature.
Disclaimer:
This testing was adopted and its performance characteristics were determined by the Molecular Diagnostics Laboratory at the American University of Beirut Medical Center. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes.
Interpretation is done by Rami Mahfouz, MD on 26/01/22 at 09:24 PM.
- الجنس
- ذكر
- الحالة الاجتماعية
- متزوج
- العمر
- 55
- الطول
- 170
- الوزن
- 86
- طبيعة العمل
- دكتور اشعة
- الحالة النفسية
- جيدة
- أمراض مزمنة
- سرطان
- أدوية مستخدمة
- Irinotican سابقا
- تشخيص الطبيب
- سرطان